(lp0
S"Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies ... Motley Fool - Mar 14, 2017 It's been an up-and-down ride for Celldex Therapeutics  shareholders since the biotech reported the late-stage failure for Rintega.Analyst Activity  Jefferies Group LLC Lowers Its Price Target On Celldex ... - Market ExclusiveCelldex Therapeutics Inc.  Moves Higher on Volume Spike for March 15 - Equities.com"
p1
aS"Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why Motley Fool - Mar 7, 2017 Shares of Celldex Therapeutics, Inc.  a clinical-stage biotech developing targeted cancer therapies, were down about 10% as of 2:45 p.m.Celldex Therapeutics  Q4 Earnings: What's in Store? - Yahoo Finance"
p2
aS'Better Buy: Agenus Inc. vs. Celldex Therapeutics Motley Fool - Mar 10, 2017 Agenus Inc  and Celldex Therapeutics, Inc.  bear an uncanny resemblance to each other. Both clinical-stage biotechs are focused on developing novel cancer therapies and reported clinical-trial failures with vaccine&nbsp;...Stocks That Should Be on Your Watchlist- Celldex Therapeutics, Inc. '
p3
aS"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics Inc Motley Fool - Feb 28, 2017 Celldex Therapeutics, Inc.  and Juno Therapeutics Inc  are two of last year's worst-performing biotech stocks.Celldex Therapeutics Inc.  Soars 9.82% on February 27 - Equities.comShares of Celldex Therapeutics, Inc.  Plunge -6.59% - Energy Index"
p4
aS'Why You Should  Buy Celldex Therapeutics, Inc. Motley Fool - Dec 6, 2016 Global spending on cancer medicines is rising along with average life spans, from $107 billion last year to an estimated $150 billion by 2020.Is Celldex Therapeutics  Stock a Solid Choice Right Now? - Nasdaq'
p5
aS"Celldex Therapeutics, Inc.'s Biggest Failure in 2016 Motley Fool - Dec 15, 2016 It hasn't been a particularly good year for Celldex Therapeutics , with shares down over 75% year to date."
p6
aS'Why Celldex Therapeutics Stock Fell by Almost 10% in January Motley Fool - Feb 8, 2017 According to data from S&amp;P Global Market Intelligence, shares of the clinical-stage biotech Celldex Therapeutics  slid by 9.7% in January and did so without a clear catalyst.Zacks Provided 2 Rating to Celldex Therapeutics, Inc.  - The Newburgh PressBiotech Stocks Worth a Closer Look: Sarepta Therapeutics, Inc. (NASDAQ:SRPT ... - The Voice Registrar'
p7
aS'Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October Motley Fool - Nov 9, 2016 Shares of Celldex Therapeutics, Inc.  a clinical-stage biotech developing targeted cancer therapies, fell 22% in October, according to data from S&amp;P Global Market Intelligence.Celldex Therapeutics, Inc.  Heads Higher After It Beats Estimates - Scibility MediaCelldex Reports Third Quarter 2016 Results - GlobeNewswire '
p8
aS"Celldex Therapeutics, Inc.'s Biggest Win in 2016 Motley Fool - Dec 10, 2016 Celldex Therapeutics  saw its stock take a huge nosedive in 2016. That's what happens when your lead product flops in a late-stage clinical study.Is Celldex Therapeutics, Inc.  a Good Stock To Buy? - Insider Monkey "
p9
aS"Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 Motley Fool - Jan 5, 2017 Although a surprising trial failure made 2016 a punishing year for Celldex Therapeutics  investors, the beaten-up biotech took several wise steps that could set it up for success in 2017 and beyond."
p10
a.